C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Increase in Short InterestTicker Report • about 1 month ago
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 5,290,000 shares, a growth of...
Share to Feed
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) dropped 3.9% during mid-day trading on Wednesday . The company traded as low as $8.35 and last traded at $8.35. Approximately...
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) shares dropped 6.8% during trading on Thursday . The company traded as low as $9.92 and last traded at $10.00. Approximately 560,028 shares...
This is a signal that CCCC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that CCCC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that CCCC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain MetastasisWATERTOWN...
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest...
Algert Global LLC trimmed its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC Free Report) by 12.4% in the third quarter, according to the company in its most recent filing with the...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...